l-Carnitine uptake in differentiating human cultured muscle

Martinnzzi, A; Vergani, L; Rosa, Marcelo Prado Amaral; Angelini, C.

doi:10.1016/0167-4889(91)90102-4

Cited by 34 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Third, selected ligands otoxin 15 (2.31 ± 0.656 pmoles/mg cell protein). Carnitine 16 (0.831 ± 0.156 pmoles/mg cell protein) and IGF-1 17,18 were tested for their ability to direct a large macromolecule (avidin/␤-galactosidase) to myogenic cells in vitro.…”

Section: Most Efforts To Develop Targeted Synthetic Vectors Havementioning

confidence: 99%

Selection and use of ligands for receptor-mediated gene delivery to myogenic cells

Feero

Rosenblatt

et al. 1997

Gene Ther

View full text Add to dashboard Cite

Identification of myogenic cell targeting ligands is a critical observed in regenerating fibers of patients with Duchenne step in the development of synthetic vectors for gene delivmuscular dystrophy and the ability to direct a large enzyme ery to skeletal muscle. Here we describe the screening of conjugate to the cytoplasm of myotubes. Finally, we show six potential targeting ligands (insulin, insulin-like growth that incorporation of transferrin into an artificial virus confactor I, iron transferrin, gallium transferrin, alpha-bungarosisting of poly-L-lysine-condensed DNA coated with a lipid toxin and carnitine) for their ability to bind dystrophinshell (LPDII formulation) results in ligand-directed delivery deficient myotubes in vitro. Those ligands showing high of DNA to myogenic cells. This is the first report of gene levels of binding to myotubes were then tested on fully diftransfer to myogenic cells using a ligand-directed synthetic ferentiated, isolated, viable myofibers. Of the ligands vector. These results suggest that rational design of ligandtested, transferrin showed the most promise based on high directed, fully synthetic, gene delivery vehicles is a viable levels of binding to myogenic cells, high levels of receptor approach to skeletal muscle vector development.

show abstract

Section: Most Efforts To Develop Targeted Synthetic Vectors Havementioning

confidence: 99%

Selection and use of ligands for receptor-mediated gene delivery to myogenic cells

Feero

Rosenblatt

et al. 1997

Gene Ther

View full text Add to dashboard Cite

show abstract

“…It is important to keep in mind that using an in vitro study of human cultured muscle, Martinuzzi et al. [18] have shown that at very high concentrations of L‐carnitine, > 10 mmol l −1 , a significant uptake into the cell, probably via passive diffusion, was still seen. Therefore, based on these results, it could be predicted that the transport of L‐carnitine into muscle in vivo is not saturated at the supraphysiological concentrations obtained following i.v.…”

Section: Discussionmentioning

confidence: 99%

A pharmacokinetic model for L‐carnitine in patients receiving haemodialysis

Fornasini

Upton

Evans

2007

Brit J Clinical Pharma

View full text Add to dashboard Cite

What is already known about this subject • Carnitine is essential for fatty acid metabolism, and is obtained from the diet and endogenous synthesis. • Patients with renal failure who are on chronic haemodialysis may require carnitine supplementation. • It is known that carnitine depletion in these patients may take years to develop, and that measurements of plasma carnitine may not be predictive of loss of carnitine from muscle, the main pool of carnitine in the body. What this study adds • This paper adds a quantitative understanding of the time‐course of the relationship between haemodialysis and the plasma concentration of L‐carnitine, with particular reference to how the carnitine pools in the body re‐equilibrate after a dialysis session. • It also provides insight into the time‐course of the depletion of L‐carnitine in these patients. Aims Patients requiring chronic haemodialysis may develop a secondary carnitine deficiency through dialytic loss of L‐carnitine. A previous report has described the plasma concentrations of L‐carnitine in 12 such patients under baseline conditions and after L‐carnitine administration (20 mg kg−1). A three‐compartment pharmacokinetic model was developed to describe these data to make inferences about carnitine supplementation in these patients. Methods L‐carnitine removal was mediated solely by intermittent haemodialysis, which was incorporated into the model as an experimentally derived dialysis clearance value that was linked to an on‐off pulse function. Data were described by a model with a central compartment linked to ‘fast’‐ and ‘slow’‐equilibrating peripheral compartments. Results The model adequately described the changing plasma concentrations of endogenous L‐carnitine in individual haemodialysis patients. Based on pooled data (mean ± SD; n = 12), the volume of the central compartment was 10.09 ± 0.72 l and the transfer rate constants into and out of the slowly equilibrating pool were 0.100 ± 0.018 h−1 and 0.00014 ± 0.00016 h−1, respectively. The turnover time of L‐carnitine in the slow pool (which was assumed to represent muscle) was approximately 300 days. The model was in general agreement with separate data on the measured loss of carnitine from muscle in dialysis patients. Conclusions Haemodialysis causes rapid reductions in plasma L‐carnitine concentrations with each dialysis session. Plasma concentrations are restored between sessions by redistribution from peripheral compartments. However, during chronic haemodialysis, the ongoing dialytic loss of L‐carnitine may lead to a slow depletion of the compound, contributing to a possible secondary deficiency.

show abstract

“…Primary human fibroblasts were obtained from healthy subjects by dissociated cell suspension in trypsin, as described previously (Martinuzzi et al ., ), with primary myoblasts obtained as previously described (Loro et al ., ) (the human samples were obtained according to European and Italian laws on tissue donation for research). Fibroblasts were grown in DMEM supplemented with 20% fetal bovine serum (FBS; Gibco, Invitrogen, Milan, Italy), 3.3 µg/ml Fungizone (Amphotericin B, Bristol‐Myers‐Squibb, Rome, Italy), 25 ng/ml fibroblasts growth factor (human FGF‐basic; Pepro Tech EC), penicillin–streptomycin, amino acids and vitamins.…”

Section: Methodsmentioning

confidence: 99%

In vitrodevelopment of engineered muscle using a scaffold based on the pressure-activated microsyringe (PAM) technique

Cei

Malena

Maria

et al. 2014

J Tissue Eng Regen Med

View full text Add to dashboard Cite

The development of new human skeletal muscle tissue is an alternative approach to the replacement of tissue after severe damage, for example in the case of traumatic injury, where surgical reconstruction is often needed following major loss of natural tissue. Treatment to date has involved the transfer of muscle tissue from other sites, resulting in a functional loss and volume deficiency of donor sites. Approaches that seek to eliminate these problems include the relatively new solution of skeletal muscle engineering. Here there are two main components to consider: (a) the cells with their regenerative potential; and (b) the polymeric structure onto which cells are seeded and where they must perform their activities. In this paper we describe well-defined two- and three-dimensional polymeric structures able to drive the myoblast process of adhesion, proliferation and differentiation. We examine a series of polymers and protein adhesions with which to functionalize the structures, and cell-seeding methods, with a view to defining the optimal protocol for engineering skeletal muscle tissue. All polymer samples were tested for their mechanical and biological properties, to support the validity of our results in the real context of muscle tissue engineering. Copyright © 2014 John Wiley & Sons, Ltd.

show abstract

l-Carnitine uptake in differentiating human cultured muscle

Cited by 34 publications

References 26 publications

Selection and use of ligands for receptor-mediated gene delivery to myogenic cells

Selection and use of ligands for receptor-mediated gene delivery to myogenic cells

A pharmacokinetic model for L‐carnitine in patients receiving haemodialysis

In vitrodevelopment of engineered muscle using a scaffold based on the pressure-activated microsyringe (PAM) technique

Contact Info

Product

Resources

About